<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="8899" end="8903" sStart="8878" offset="21" sid="r7.1.use.v.0402" wn="1" wnkey="use%2:34:01::" annotator="jeneale" text="The dosage used was 600R (6 Gy)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="490" end="501" sStart="null" offset="0" sid="null" wn="2" wnkey="transfer%2:40:01::" annotator="veweser" text="However, when T cells reactive against tumor antigens are expanded ex vivo and then &lt;b&gt;transferred&lt;/b&gt; back into tumor-bearing hosts, results have been mixed in treating both melanoma [ 2 3 4 ] and lymphoma [ 5 6 7 ] . Several explanations for these variable results have been suggested by studies of T cell immunity in mice, involving experimental tumors derived from inoculation of cell lines." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="24157" end="24168" sStart="null" offset="0" sid="null" wn="2 3" wnkey="null" annotator="tofox" text="Previous studies have shown that adoptively &lt;b&gt;transferred&lt;/b&gt; tumor antigen-specific CD4 +T cells can be tolerized in the secondary lymphoid organs [ 9 34 ] , including the RIP-Tag2 model [ 30 ] . Radiation may kill or disable regulatory T cells [ 35 36 ] , or other bone marrow-derived tolerizing cells and prevent the induction of tolerance in adoptively &lt;b&gt;transferred&lt;/b&gt; tumor-specific T cells [ 9 ] . Additionally, the high but sub-lethal dose of radiation used leads to significant lymphopenia [ 37 ] . The sudden reduction in lymphocyte number may create the spatial allowance in spleen and lymph nodes necessary for the homing, activation and expansion of he adoptively-transferred T cells." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="24157" end="24168" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="Previous studies have shown that adoptively &lt;b&gt;transferred&lt;/b&gt; tumor antigen-specific CD4 +T cells can be tolerized in the secondary lymphoid organs [ 9 34 ] , including the RIP-Tag2 model [ 30 ] . Radiation may kill or disable regulatory T cells [ 35 36 ] , or other bone marrow-derived tolerizing cells and prevent the induction of tolerance in adoptively &lt;b&gt;transferred&lt;/b&gt; tumor-specific T cells [ 9 ] . Additionally, the high but sub-lethal dose of radiation used leads to significant lymphopenia [ 37 ] . The sudden reduction in lymphocyte number may create the spatial allowance in spleen and lymph nodes necessary for the homing, activation and expansion of he adoptively-transferred T cells." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="23810" end="23821" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="Previous studies have shown that adoptively &lt;b&gt;transferred&lt;/b&gt; tumor antigen-specific CD4 +T cells can be tolerized in the secondary lymphoid organs [ 9 34 ] , including the RIP-Tag2 model [ 30 ] . Radiation may kill or disable regulatory T cells [ 35 36 ] , or other bone marrow-derived tolerizing cells and prevent the induction of tolerance in adoptively &lt;b&gt;transferred&lt;/b&gt; tumor-specific T cells [ 9 ] . Additionally, the high but sub-lethal dose of radiation used leads to significant lymphopenia [ 37 ] . The sudden reduction in lymphocyte number may create the spatial allowance in spleen and lymph nodes necessary for the homing, activation and expansion of he adoptively-transferred T cells." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="5135" end="5146" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="Crosses of Rip1-Tag5 mice to transgenic mice that either increased the abundance of anti-Tag CD4 +T cells (TCR1) [ 28 ] or rendered the tumor cells co-stimulatory (Rip-B7-1) [ 31 ] dramatically enhanced the infiltration of premalignant lesions, but not of solid tumors [ 22 ] . Additionally, ex vivo stimulated Tag-specific CD4 +T cells were &lt;b&gt;transferred&lt;/b&gt; into Rip1-Tag5." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="26076" end="26087" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="It is possible that radiation-induced, tumor-infiltrating dendritic cells may facilitate sustained activation and infiltration of the adoptively &lt;b&gt;transferred&lt;/b&gt; CD4 +T cells in solid tumors in the combination group." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="490" end="501" sStart="null" offset="0" sid="null" wn="2" wnkey="transfer%2:40:01::" annotator="jeneale" text="However, when T cells reactive against tumor antigens are expanded ex vivo and then &lt;b&gt;transferred&lt;/b&gt; back into tumor-bearing hosts, results have been mixed in treating both melanoma [ 2 3 4 ] and lymphoma [ 5 6 7 ] . Several explanations for these variable results have been suggested by studies of T cell immunity in mice, involving experimental tumors derived from inoculation of cell lines." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="24157" end="24168" sStart="null" offset="0" sid="null" wn="4 3" wnkey="null" annotator="carichter" text="Previous studies have shown that adoptively &lt;b&gt;transferred&lt;/b&gt; tumor antigen-specific CD4 +T cells can be tolerized in the secondary lymphoid organs [ 9 34 ] , including the RIP-Tag2 model [ 30 ] . Radiation may kill or disable regulatory T cells [ 35 36 ] , or other bone marrow-derived tolerizing cells and prevent the induction of tolerance in adoptively &lt;b&gt;transferred&lt;/b&gt; tumor-specific T cells [ 9 ] . Additionally, the high but sub-lethal dose of radiation used leads to significant lymphopenia [ 37 ] . The sudden reduction in lymphocyte number may create the spatial allowance in spleen and lymph nodes necessary for the homing, activation and expansion of he adoptively-transferred T cells." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="21114" end="21125" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="carichter" text="Previous studies using lethal dose radiation and bone marrow transplant prior to CD4 +T cell transfer in another Rip-Tag line of mice indicated that such treatment could produce a modest increase in the number of tumor-infiltrating T cells [ 22 ] . The current study extends the thesis by focusing on the use of sub-lethal radiation to enhance the anti-tumor immunity of adoptively &lt;b&gt;transferred&lt;/b&gt; tumor-antigen-specific lymphocytes in Rip1-Tag2 mice." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="22938" end="22949" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="carichter" text="We speculate that the tumor-infiltrating, CD4 +T cells would induce the activation and tumor-infiltration of CD8 +T cells present in the &lt;b&gt;transferred&lt;/b&gt; transgenic splenocytes." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="490" end="501" sStart="null" offset="0" sid="null" wn="2" wnkey="transfer%2:40:01::" annotator="carichter" text="However, when T cells reactive against tumor antigens are expanded ex vivo and then &lt;b&gt;transferred&lt;/b&gt; back into tumor-bearing hosts, results have been mixed in treating both melanoma [ 2 3 4 ] and lymphoma [ 5 6 7 ] . Several explanations for these variable results have been suggested by studies of T cell immunity in mice, involving experimental tumors derived from inoculation of cell lines." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="27613" end="27622" sStart="null" offset="19" sid="r8.suggest.v.0611" wn="3" wnkey="suggest%2:32:02::" annotator="brubin" text="A recent study has suggested that tumor-specific, CD4 +T cells can exert anti-tumor effects by inhibiting angiogenesis via release of IFN-? [ 11 ] . Thus, the &quot;white&quot; tumors noted in the current study may be indicative of angiogenic inhibition by the infiltrating tumor-specific, CD4 +T cells, and such inhibition may be relevant to the observed efficacy." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="7493" end="7501" sStart="null" offset="20" sid="r11.refer.v.0943" wn="7" wnkey="refer%2:32:04::" annotator="vebatchelder" text="Tag-TCR1 (referred to hereafter as TCR) transgenic mice expressing a T cell receptor transgene with specificity to Tag were generated in the B6D2F1 background and backcrossed to C3HeBFe for 20 generations [ 28 ] . About 10% of the splenic CD4 +T cells in this transgenic line express the TCR transgene [ 28 ] . All Rip1-Tag2 in all treatment groups received the same diet throughout the experiment." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="11800" end="11811" sStart="null" offset="6" sid="r11.recommend.v.0025" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="3) at recommended concentrations (PharMingen, San Diego, CA)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="11800" end="11811" sStart="null" offset="6" sid="r11.recommend.v.0025" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="3) at recommended concentrations (PharMingen, San Diego, CA)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="6164" end="6169" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="veweser" text="We chose the Rip1-Tag2 line, for its phenotype of &lt;b&gt;rapid&lt;/b&gt;, largely synchronous tumorigenesis, and its systemic tolerance, reasoning that effects of experimental manipulations could be readily distinguished." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-11.anc" start="6164" end="6169" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="tofox" text="We chose the Rip1-Tag2 line, for its phenotype of &lt;b&gt;rapid&lt;/b&gt;, largely synchronous tumorigenesis, and its systemic tolerance, reasoning that effects of experimental manipulations could be readily distinguished." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="10233" end="10243" sStart="null" offset="47" sid="r10.particular.j.0594" wn="2" wnkey="particular%5:00:02:specific:00" annotator="anfahmy" text="Such tumors are associated with this particular line of Rip-Tag transgenic mice (but not others) and were not the result of any of the treatments in the study." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="17027" end="17034" sStart="null" offset="113" sid="r8.number.n.0087" wn="1" wnkey="number%1:07:00::" annotator="veweser" text="One should recall that the TCR mice express a CD4-restricted TCR, and thus produce increased numbers of anti-Tag CD4 T cells, and thus we anticipated a bias in numbers toward this T cell type." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="17027" end="17034" sStart="null" offset="113" sid="r8.number.n.0087" wn="1" wnkey="number%1:07:00::" annotator="jeneale" text="One should recall that the TCR mice express a CD4-restricted TCR, and thus produce increased numbers of anti-Tag CD4 T cells, and thus we anticipated a bias in numbers toward this T cell type." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="17027" end="17034" sStart="null" offset="113" sid="r8.number.n.0087" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="One should recall that the TCR mice express a CD4-restricted TCR, and thus produce increased numbers of anti-Tag CD4 T cells, and thus we anticipated a bias in numbers toward this T cell type." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="17027" end="17034" sStart="null" offset="113" sid="r8.number.n.0087" wn="1" wnkey="number%1:07:00::" annotator="brubin" text="One should recall that the TCR mice express a CD4-restricted TCR, and thus produce increased numbers of anti-Tag CD4 T cells, and thus we anticipated a bias in numbers toward this T cell type." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="23995" end="23999" sStart="null" offset="237" sid="r9.kill.v.0879" wn="1" wnkey="kill%2:35:00::" annotator="cgozo" text="Previous studies have shown that adoptively transferred tumor antigen-specific CD4 +T cells can be tolerized in the secondary lymphoid organs [ 9 34 ] , including the RIP-Tag2 model [ 30 ] . Radiation may kill or disable regulatory T cells [ 35 36 ] , or other bone marrow-derived tolerizing cells and prevent the induction of tolerance in adoptively transferred tumor-specific T cells [ 9 ] . Additionally, the high but sub-lethal dose of radiation used leads to significant lymphopenia [ 37 ] . The sudden reduction in lymphocyte number may create the spatial allowance in spleen and lymph nodes necessary for the homing, activation and expansion of he adoptively-transferred T cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="128" end="133" sStart="null" offset="85" sid="r8.1.great.j.0284" wn="1" wnkey="great%5:00:01:large:00" annotator="cgozo" text="With breakthroughs in molecular biology, basic immunology and biotechnology, great progress has been made in the field of tumor immunology." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="14604" end="14612" sStart="null" offset="232" sid="r10.control.n.0990" wn="4" wnkey="control%1:09:02::" annotator="anfahmy" text="The tumor burden of the untreated control group at the end of the study was ~146 mm 3. No reduction in tumor burden was observed following adoptive transfer of non-transgenic splenocytes alone (132% of controls)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="15157" end="15168" sStart="null" offset="56" sid="null" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="Thus, even with substantial tumor burden, the combination of sub-lethal radiation and splenocyte transfer could stop tumor growth during the course of the study." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="28582" end="28593" sStart="null" offset="77" sid="r11.combination.n.0940" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="While the underlying mechanisms remain unknown, it is evident that a combination of sub-lethal radiation and the transfer of tumor-specific CD4 +lymphocytes can have a synergistic effect on tumor regression." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="15418" end="15429" sStart="null" offset="12" sid="r11.combination.n.0610" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="Because the combination of sub-lethal radiation and TCR splenocyte transfer lead to significant reduction in tumor burden in both intervention and regression trials, we asked whether the radiation had increased the number of tumor-infiltrating lymphocytes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="15157" end="15168" sStart="null" offset="56" sid="null" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Thus, even with substantial tumor burden, the combination of sub-lethal radiation and splenocyte transfer could stop tumor growth during the course of the study." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="27426" end="27437" sStart="null" offset="80" sid="r11.combination.n.0875" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="The hemorraghic phenotype persisted in all single agent trials, but the combination trial was distinct." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="13588" end="13599" sStart="null" offset="9" sid="r11.combination.n.0722" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="With the combination treatment, a significant reduction in both tumor volume (87%; p = 0.0004) and tumor number was observed." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="19618" end="19629" sStart="null" offset="19" sid="r11.combination.n.0632" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Because the single combination treatment lead to clear therapeutic benefits and yet did not eradicate established tumors, we asked whether mice would benefit from repeated treatments." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="13777" end="13788" sStart="null" offset="52" sid="r11.combination.n.0509" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="It is notable that the mice receiving the combination treatment had a mean tumor volume of 4.6 mm 3(p = 0.0004) and an average tumor number of 2.3, comparable to the situation at the beginning of the trial." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="15157" end="15168" sStart="null" offset="56" sid="r11.combination.n.0236" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Thus, even with substantial tumor burden, the combination of sub-lethal radiation and splenocyte transfer could stop tumor growth during the course of the study." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="5792" end="5803" sStart="null" offset="86" sid="r11.combination.n.0197" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Sub-lethal irradiation has been successfully used to decrease tumor burden in combination with a cytokine-producing tumor vaccine in a murine renal cell carcinoma lung metastases model [ 32 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="26132" end="26143" sStart="null" offset="225" sid="r11.combination.n.0056" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="It is possible that radiation-induced, tumor-infiltrating dendritic cells may facilitate sustained activation and infiltration of the adoptively transferred CD4 +T cells in solid tumors in the combination group." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="19919" end="19930" sStart="null" offset="40" sid="r11.combination.n.0037" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Rip1-Tag2 mice were given the combination treatment at 10-weeks and again at 13-weeks of age for an intervention trial, or at 13 and 16-weeks for a regression trial." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="15157" end="15168" sStart="null" offset="56" sid="null" wn="1" wnkey="combination%1:14:00::" annotator="adelpriore" text="Thus, even with substantial tumor burden, the combination of sub-lethal radiation and splenocyte transfer could stop tumor growth during the course of the study." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="16680" end="16691" sStart="null" offset="243" sid="r11.combination.n.0783" wn="1" wnkey="combination%1:14:00::" annotator="adelpriore" text="However, in both intervention and regression trials, significant CD4 +T cell and CD8 +T cell infiltration into hyperplastic/dysplastic islets and tumors was noted in Rip1-Tag2 mice that had received the combination of sub-lethal radiation and adoptive transfer of TCR splenocytes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="16893" end="16904" sStart="null" offset="115" sid="r11.combination.n.0159" wn="7" wnkey="combination%1:04:00::" annotator="adelpriore" text="A modest increase in CD11c +dendritic cell infiltration was observed in the mice receiving the combination therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="26132" end="26143" sStart="null" offset="225" sid="r11.combination.n.0056" wn="2147483646" wnkey="null" annotator="adelpriore" text="It is possible that radiation-induced, tumor-infiltrating dendritic cells may facilitate sustained activation and infiltration of the adoptively transferred CD4 +T cells in solid tumors in the combination group." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="19919" end="19930" sStart="null" offset="40" sid="r11.combination.n.0037" wn="2147483646" wnkey="null" annotator="adelpriore" text="Rip1-Tag2 mice were given the combination treatment at 10-weeks and again at 13-weeks of age for an intervention trial, or at 13 and 16-weeks for a regression trial." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-11.anc" start="18376" end="18383" sStart="null" offset="151" sid="r11.benefit.n.0739" wn="2" wnkey="benefit%1:07:00::" annotator="vebatchelder" text="Because splenocyte transfer alone had resulted in no significant reduction in tumor burden, this group was not tested for survival benefit, for logistical reasons." />
  </sentences>
</list>